IMRT 2018

Multicentric Fase II trial

2012 - 2015, N: 170 patients (urethra sparing)

Results (ESTRO 2018)- Follow-up of 18-month good tolerance and toxicity profile of both treatment arms in this study with minimal impact on GU QoL.